Literature DB >> 371915

Ascites: its correction by peritoneovenous shunting.

H H LeVeen, S Wapnick, C Diaz, S Grosberg, M Kinney.   

Abstract

Patients with refractory ascites and HRS should be considered to present an urgent indication for peritoneovenous shunting. The shunt offers a method of continuous reinfusion of ascitic fluid which corrects avid sodium retention, oliguria and azotemia. Severe encephalopathy, jaundice or peritoneal sepsis--common complications of cirrhosis--contraindicate installation of the shunt before improvement occurs. Associated cardiac disease does not contraindicate the use of the shunt provided that ascitic fluid is removed at the time of operation and large amounts of diuretics are used. This operation has also proved useful in ascites attributed to causes other than cirrhosis. The main complications include disseminated intravascular coagulopathy, hepatic coma and sepsis in a few patients. Results of a randomized prospective study indicate that the shunt should probably be considered in patients with diet-resistant massive ascites even before they prove to be refractory to diuretic therapy.

Entities:  

Mesh:

Year:  1979        PMID: 371915     DOI: 10.1016/s0011-3840(79)80001-5

Source DB:  PubMed          Journal:  Curr Probl Surg        ISSN: 0011-3840            Impact factor:   1.909


  4 in total

1.  General surgery-important advances in clinical medicine: ascites and the peritoneovenous shunt.

Authors:  A E Yellin
Journal:  West J Med       Date:  1983-02

Review 2.  [Peritoneovenous shunt in the treatment of therapy-refractory ascites].

Authors:  C A Eriksen; A Cuschieri
Journal:  Langenbecks Arch Chir       Date:  1988

3.  Experimental and clinical experiences with peritoneo-venous shunt (locally made Z-CI device) in the treatment of intractable ascites.

Authors:  Z Xu; M F Jin
Journal:  Acta Acad Med Wuhan       Date:  1983

4.  Implantation of a skin graft tube to create a saphenoperitoneal shunt for refractory ascites.

Authors:  Ahmed E Lasheen; Awni Elzeftawy; Samir Ibrahim; Mohammed Attia; Mohammed Emam
Journal:  Surg Today       Date:  2007-06-26       Impact factor: 2.549

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.